FindTrial
Sign In

J1I-MC-GZBN:A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503660-17-00
Acronym
J1I-MC-GZBN
Enrollment
65
Registered
2023-09-15
Start date
2023-10-09
Completion date
2025-10-28
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee, Obesity, Osteoarthritis, Overweight

Brief summary

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score, Percent Change from Baseline in Body Weight

Interventions

DRUGRetatrutide
DRUGPlacebo Injection

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score, Percent Change from Baseline in Body Weight—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026